One Boston Scientific Place
Natick MA 01760-1537 USA [t] +1 888-272 1001
Boston Scientific is a medical device company dedicated to developing less-invasive medical devices and procedures. The company delivers more than 15,000 products in over 45 countries and operates 26 manufacturing, distribution and technology centres.
Diversity study shows US stent usage for minority patients
18 November, 2016
Under-served patient population in America comes under scrutiny in study by Boston Scientific on health equality within the country
Gastrointestinal specialist company acquisition
30 September, 2016
Boston Scientific has bought into gastrointestinal treatment with the acquisition of EndoChoice Holdings
CE mark for transcatheter aortic valve system
23 September, 2016
The Lotus Edge trancatheter aortic valve implantation system from Boston Scientific has gained the CE mark for use in European markets
FDA approval for subcutaneous implantable defibrillator
02 September, 2016
Approvals have been given allowing patients to receive treatment using implantable defibrillator equipment from Boston Scientific
Good 12 month trial results for leg stent
29 September, 2015
Best ever trail results have been recorded for the Eluvia vascular stent used for treating the narrowing or blockage of arteries
Warfarin alternative device gains FDA approval
23 March, 2015
The Watchman Left Atrial Appendage Closure Device from Boston Scientific gains FDA approval and could mean more patients can receive a non-drug alternative to Warfarin
Visualisation system for diagnosis of pancreatic ducts
02 March, 2015
The SpyGlass DS Direct visualisation system from Boston Scientific simplifies diagnostics for liver, gallbladder, pancreas and bile duct problems
Pacemaker CE mark with options for magnetic resonance imaging (MRI)
26 October, 2014
Boston Scientific Corporation has received CE Mark approval for the Accolade pacemaker family. When implanted with the company's Ingevity leads, Accolade pacemakers enable patients to receive full-body MRI scans in both 1.5 Tesla and 3.0 Tesla systems. In addition, the Boston Scientific ImageReady technology offers flexible MRI option, allowing higher energy scan sequences, featuring a programmable MRI timer designed to improve patient workflow.
Journal publishes implantable defibrillator trial results
07 April, 2014
Interim results for the safety and effectiveness of a subcutaneous implantable defibrillator have been published in the European Heart Journal
Long term results from CRT Defibrillator use
03 April, 2014
Cardiac resynchronisation therapy using CRT defibrillators shows promising results after long term implantation trial
European approval for coronary stent
18 March, 2014
A platinum chromium coronary stent system from Boston Scientific will bring benefit to coronary patients in Europe after receiving CE approval
CE Mark achieved for oesophageal stent
17 February, 2014
The WallFlex oesophageal stent from Boston Scientific has received CE Mark for the treatment of oesophageal strictures in Europe
Re-entry catheter system for treating artery blockages
06 February, 2014
The OffRoad Re-Entry Catheter System from Boston Scientific is now being used for treating completely blocked leg arteries in the USA
Interventional cardiology specialist joins Boston Scientific
07 January, 2014
Boston Scientific has appointed an eminent specialist as the new chief medical officer and senior VP of Interventional Cardiology
Cardiac implant system CE approval
19 December, 2013
Boston Scientific gains CE approval on quadripolar CRT-D Systems for use with cardiac patients
FDA casts favourable vote on Left Atrial Appendage Closure device
12 December, 2013
Boston Scientific gains favourable result from FDA vote on benefits of the Watchman left atrial appendage closure device
Spinal implant results show effectiveness in treating chronic pain
10 December, 2013
Neuromodulation Society event presented with results of tests of the effectiveness in the treatment of chronic pain of the Precision Spectra spinal implant system
Support agreement for drug eluting stents
09 December, 2013
The Medicines Company enters agreement with Boston Scientific on providing support for hospitals using the Promus Premier drug eluting stent system
FDA approval for new drug-eluting stent
26 November, 2013
The Promus Premier Everolimus-eluting stent for use in coronary arteries has received approval from the food and drug administration
Microcatheter provides access to difficult blood vessels
21 November, 2013
Direxion Torqueable Microcatheter from Boston Scientific available for interventional radiology treatments
First Lotus valve implants take place in EU
18 November, 2013
Implants of transcatheter aortic valves have taken place in Germany using Boston Scientific's Lotus valve system
Acquisition provides access to electrophysiology markets
05 November, 2013
Boston Scientific has completed the transaction to acquire Bard EP and gain access to global markets for eletrophysiology equipment
Aortic valve replacement device meets key performance measures
04 November, 2013
Data presented at the TCT Conference shows how the Lotus Valve system for use with severe aortic valve stenosis patients has met key performance requirements
Data presented on effectiveness of Vessix renal denervation
30 October, 2013
Boston Scientific has been demonstrating the effective use of the Vessix system for renal denervation using low power radio frequency energy
CE approval for aortic valve replacement technology
29 October, 2013
The Lotus Valve transcatheter aortic valve replacement system from Boston Scientific has received CE approval
Chinese approval for bronchial thermoplasty system
28 October, 2013
Alair bronchial thermoplasty system to be used in China for the treatment of patients with severe asthma
Award for subcutaneous implantable defibrillator
24 October, 2013
Boston Scientific has been recognised for best medical technology for its subcutaneous implantable defibrillator
Clinical trials begin on femoral artery drug-eluting stent
10 October, 2013
A New Zealand hospital has begun clinical trials on the use of the Innova drug eluting stent system for correcting problems in arteries above the knee
Chinese innovation centre to assist local medics
18 September, 2013
Medical practicioners in China will benefit from an innovation centre in the country opened by Boston Scientific
Clinical trial population for eluting stent system completed
13 September, 2013
Boston Scientific has reached a key point in its clinical trials for the Synergy eluting stent system for the treatment of atherosclerotic coronary lesions
Severe asthma treatment with bronchial thermoplasty
06 September, 2013
US medical journal publishes results of five years study into the use of the Alair Bronchial Thermoplasty system from Boston Scientific on severe asthma patients
Live webcast of QA session at healthcare conference
04 September, 2013
Members of Boston Scientific will be attending the Morgan Stanley Global Healthcare conference with live webcast of their question and answer session
Boston Scientific receives FDA approval for IntellaTip MiFi XP ablation catheter
22 August, 2013
Boston Scientific continues to expand its electrophysiology (EP) offerings with US Food and Drug Administration (FDA) approval of its IntellaTip MiFi XP catheter and 510(k) clearance of its Zurpaz 8.5F steerable sheath.
Boston Scientific completes enrollment in SuperNOVA trial to evaluate Innova Self-Expanding Stent System
20 August, 2013
Boston Scientific completes enrollment in the SuperNOVA trial - a global, single arm, prospective, multicenter trial evaluating the long-term (12 month) safety and effectiveness of the Innova Self-Expanding Stent System (Innova Stent System).
Boston Scientific launches guide extension catheter in USA and Europe
15 July, 2013
Boston Scientific receives US Food and Drug Administration 510(k) clearance and CE Mark approval for the Guidezilla Guide Extension Catheter and has launched the device in the USA and Europe.
First implant of Boston Scientific Vitalio pacemaker is performed in Europe
28 June, 2013
The first patient implant of the Boston Scientific VITALIO pacemaker is performed at ZGT Hengelo in Hengelo, the Netherlands.
Boston Scientific pacemaker family adjusts pacing to respiration
27 June, 2013
Boston Scientific is launching a new family of pacemakers in Europe which monitor respiration, adjust pacing accordingly, and support insight into the patient's overall heart failure status.
Study shows deep brain stimulation system improves motor function for patients with Parkinson's disease
18 June, 2013
Patients with Parkinson's disease using the Boston Scientific's Vercise DBS (deep brain stimulation) System are showing an improvement in motor scores according to interim data from the VANTAGE DBS study.
Boston Scientific collaborates with pelvic floor disorders network to study treatment strategies for uterine prolapse
04 June, 2013
Boston Scientific is continuing to demonstrate the company's commitment to women's health by providing a research and education grant of more than $1 million to the Pelvic Floor Disorders Network (PFDN) for the SUPeR clinical trial.
Two trials show positive results for drug-eluting stent technologies treating coronary heart disease
27 May, 2013
Boston Scientific reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are emerging treatment options for coronary heart disease.
Boston Scientific completes first-in-human clinical trial of ablation catheter for patients with Type 1 atrial flutter
08 May, 2013
Boston Scientific completes a first-in-human clinical trial utilising the IntellaTip MiFi XP Ablation Catheter for the treatment of type 1 atrial flutter, an arrhythmia originating in the right atrium of the heart that affects nearly one million people in the USA.
Boston Scientific acquires Fixate tissue band for spinal cord stimulator leads and pain pump catheters
17 April, 2013
Boston Scientific acquires the fiXate Tissue Band and is launching the product in the USA.
Boston Scientific starts clinical trial to evaluate new pacer in MRI environment
16 April, 2013
The first patient in the USA is implanted with the Boston Scientific next generation ImageReady MR Conditional pacing system in the SAMURAI clinical trial.
Boston Scientific receives US FDA approval for spinal cord stimulator system
15 April, 2013
Boston Scientific receives approval by the US Food and Drug Administration and is beginning a limited launch of the Precision Spectra Spinal Cord Stimulator (SCS) System.
Boston Scientific Watchman device demonstrates positive clinical outcomes for AF patients
12 March, 2013
Boston Scientific is reporting preliminary data in the PREVAIL clinical trial meets two out of three co-primary endpoints.
Support catheter tool assists treatment of Peripheral Arterial Disease
11 March, 2013
Boston Scientific is launching the company's 0.035inch and 0.018inch Rubicon Support Catheter in the USA.
Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary stent receives CE Mark approval
14 February, 2013
Boston Scientific receives CE Mark approval for the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's next-generation durable polymer drug-eluting stent (DES) technology, and is starting its European market launch.
Open-irrigated temperature ablation catheter clinical trial sees first patient treated
17 January, 2013
The first patient has been treated in the Boston Scientific ZERO AF clinical trial to evaluate the safety and effectiveness of the Blazer Open-Irrigated Temperature Ablation Catheter in patients with symptomatic, drug refractory paroxysmal atrial fibrillation.
Boston Scientific starts clinical trial of patients implanted with next generation pacing leads
17 December, 2012
The first patient is implanted with the Boston Scientific's next generation INGEVITY pacing leads in a clinical trial designed to establish the safety, performance and effectiveness of the leads.
First patient enrolls in multicentre study of the SYNERGY coronary stent system
03 December, 2012
The first patient enrolls in the Boston Scientific EVOLVE II clinical trial, which is designed to further assess the safety and effectiveness of the SYNERGY Stent System and support US Food and Drug Administration and Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions.